Tags

Type your tag names separated by a space and hit enter

Treatments for Crohn's disease that minimise steroid doses are associated with a reduced risk of osteoporosis.
Clin Nutr. 2001 Dec; 20(6):541-6.CN

Abstract

Crohn's disease is associated with an increased prevalence of osteoporosis. Corticosteroids, commonly used to control exacerbations, appear to be a major risk factor for subsequent development of osteoporosis. Exclusion diets, avoiding foods that precipitate symptoms, frequently allow control of the disease avoiding the use of corticosteroids and may thereby reduce the risk of osteoporosis. To investigate this we performed bone mineral density measurements of the proximal femur and spine in 95 patients, 31 treated predominately by corticosteroids, 33 by dietary manipulation with a low life-time corticosteroid dose and 31 by treatments other than diets but also with a low life-time corticosteroid dose. In both groups with a low life-time corticosteroid dose bone mineral density was comparable to that of age-matched normal controls, whereas bone mineral density was significantly reduced in those treated predominately by corticosteroids. We conclude that corticosteroid therapy is an independent risk factor for osteoporosis in patients with Crohn's disease and should be used as little as possible.

Authors+Show Affiliations

Department of Gastroenterology, Addenbrooke's Hospital NHS Trust, Cambridge, UK.No affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

11884003

Citation

Dear, K L., et al. "Treatments for Crohn's Disease That Minimise Steroid Doses Are Associated With a Reduced Risk of Osteoporosis." Clinical Nutrition (Edinburgh, Scotland), vol. 20, no. 6, 2001, pp. 541-6.
Dear KL, Compston JE, Hunter JO. Treatments for Crohn's disease that minimise steroid doses are associated with a reduced risk of osteoporosis. Clin Nutr. 2001;20(6):541-6.
Dear, K. L., Compston, J. E., & Hunter, J. O. (2001). Treatments for Crohn's disease that minimise steroid doses are associated with a reduced risk of osteoporosis. Clinical Nutrition (Edinburgh, Scotland), 20(6), 541-6.
Dear KL, Compston JE, Hunter JO. Treatments for Crohn's Disease That Minimise Steroid Doses Are Associated With a Reduced Risk of Osteoporosis. Clin Nutr. 2001;20(6):541-6. PubMed PMID: 11884003.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatments for Crohn's disease that minimise steroid doses are associated with a reduced risk of osteoporosis. AU - Dear,K L, AU - Compston,J E, AU - Hunter,J O, PY - 2002/3/9/pubmed PY - 2002/6/26/medline PY - 2002/3/9/entrez SP - 541 EP - 6 JF - Clinical nutrition (Edinburgh, Scotland) JO - Clin Nutr VL - 20 IS - 6 N2 - Crohn's disease is associated with an increased prevalence of osteoporosis. Corticosteroids, commonly used to control exacerbations, appear to be a major risk factor for subsequent development of osteoporosis. Exclusion diets, avoiding foods that precipitate symptoms, frequently allow control of the disease avoiding the use of corticosteroids and may thereby reduce the risk of osteoporosis. To investigate this we performed bone mineral density measurements of the proximal femur and spine in 95 patients, 31 treated predominately by corticosteroids, 33 by dietary manipulation with a low life-time corticosteroid dose and 31 by treatments other than diets but also with a low life-time corticosteroid dose. In both groups with a low life-time corticosteroid dose bone mineral density was comparable to that of age-matched normal controls, whereas bone mineral density was significantly reduced in those treated predominately by corticosteroids. We conclude that corticosteroid therapy is an independent risk factor for osteoporosis in patients with Crohn's disease and should be used as little as possible. SN - 0261-5614 UR - https://www.unboundmedicine.com/medline/citation/11884003/Treatments_for_Crohn's_disease_that_minimise_steroid_doses_are_associated_with_a_reduced_risk_of_osteoporosis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0261-5614(01)90496-0 DB - PRIME DP - Unbound Medicine ER -